BioMarin Pharmaceutical Inc. (FRA:BM8)

Germany · Delayed Price · Currency is EUR

47.08

+0.02 (0.04%)

At close: Jan 30, 2026

Revenue

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012
VOXZOGO Revenue	862.03M	735.09M
VIMIZIM Revenue	777.62M	739.78M
NAGLAZYME Revenue	475.18M	479.58M
PALYNZIQ Revenue	408.40M	355.05M
ALDURAZYME Revenue	198.16M	183.89M
BRINEURA Revenue	184.73M	169.08M
KUVAN Revenue	104.52M	120.90M
ROCTAVIAN Revenue	33.44M	26.07M
Total Net Product Revenue	3.04B	2.81B
Royalty and Other Revenue	49.93M	44.47M
Revenue (Other)	-33.44M	-26.07M
Revenue (Total)	3.09B	2.85B

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012
Royalty and Other Revenue	49.93M	44.47M
United States Revenue	1.06B	924.81M
Europe Revenue	889.18M	829.03M
Latin America Revenue	387.18M	378.08M
Rest of World Revenue (Post-Q2 2024)	512.34M	493.63M
Revenue (Other)	198.16M	183.89M
Revenue (Total)	3.09B	2.85B

Updated Sep 30, 2025. Data Source: Fiscal.ai.